Bill
SCR 33
Declares May 23, 2025, GM1 Gangliosidosis Awareness Day in California to boost public awareness, early diagnosis, genetic counseling, and access to care and treatments.
Status: Concurrent resolution — introduced March 4, 2025; adopted by the Legislature and transmitted (sent to the Secretary of the Senate) on May 22, 2025. (Document text indicates no fiscal committee referral.)
Note on source materials: the bill header you provided (CONDOLENCES: Covington Fire Chief Gary Blocker Jr.) does not match the attached legislative text. The attached documents and bill text all concern SCR 33 (Padilla), which declares May 23, 2025, as GM1 Gangliosidosis Awareness Day in California. This summary is based on the resolution text you supplied.
Purpose and intent
- To designate May 23, 2025, as “GM1 Gangliosidosis Awareness Day” in California.
- To increase public awareness of GM1 Gangliosidosis — a rare, inherited lysosomal storage disorder that causes progressive neurodegeneration — with the goal of improving early diagnosis, access to specialized care, genetic counseling, and (when available) treatments.
Key provisions
- Legislative finding statements describing GM1 Gangliosidosis:
- Characterized as a rare inherited disease causing progressive neurodegeneration and loss of physical/developmental abilities, ultimately fatal.
- Estimated incidence: approximately 1 in 100,000 to 200,000 live births.
- Often underdiagnosed or misdiagnosed; lack of public awareness worsens access to services and appropriate care.
- Early diagnosis is important for clinical management, genetic counseling, and application of treatments as they become available.
- Resolved clauses:
- Declares May 23, 2025, as GM1 Gangliosidosis Awareness Day in California.
- Directs the Secretary of the Senate to transmit copies of the resolution to the author for distribution.
Who is affected / likely impact
- Symbolic designation with no regulatory or funding changes.
- Primary beneficiaries: individuals living with GM1 Gangliosidosis, their families and caregivers, medical and genetic counseling communities, patient advocacy and support organizations.
- Potential impacts: increased public and professional awareness may lead to earlier recognition/diagnosis, improved referrals to specialized services, greater community support, and more visibility for research or treatment initiatives.
Procedural and fiscal notes
- Classified as a concurrent resolution (expresses legislative sentiment; does not create law or appropriate funds).
- Legislative counsel’s digest indicates no fiscal committee referral (no direct fiscal impact).
- The resolution is nonbinding and ceremonial in nature; it urges awareness and distribution of the resolution copy but does not create mandates for state agencies.
If you want, I can prepare a short one‑page handout describing GM1 Gangliosidosis (symptoms, diagnosis, resources) suitable for sharing on Awareness Day.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
